Institution
Xiamen University
Education•Amoy, Fujian, China•
About: Xiamen University is a education organization based out in Amoy, Fujian, China. It is known for research contribution in the topics: Catalysis & Population. The organization has 50472 authors who have published 54480 publications receiving 1058239 citations. The organization is also known as: Amoy University & Xiàmén Dàxué.
Topics: Catalysis, Population, Graphene, Raman spectroscopy, Anode
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the authors examined dissolved oxygen (DO), the carbonate system and nutrients in the upper reach of the Pearl River estuary in a very dry season in February of 2004.
204 citations
••
TL;DR: The identification of a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals.
204 citations
••
TL;DR: A new kind of poly(dimethylsiloxane) (PDMS) oil absorbent with high absorption capacity and excellent reusability was prepared and used for oil/water separation and shows little loss of their absorption capacities and own weights.
Abstract: Cleanup of oil spills is a worldwide challenge to prevent serious environmental pollution. A new kind of poly(dimethylsiloxane) (PDMS) oil absorbent with high absorption capacity and excellent reusability was prepared and used for oil/water separation. The preparation process of PDMS oil absorbents involves direct curing of a PDMS prepolymer in a p-xylene solution in the presence of commercial sugar particles, which is simple and economic. PDMS oil absorbents have interconnected pores and a swellable skeleton, combining the advantages of porous materials and gels. Absorption capacities of PDMS oil absorbents are 4–34 g/g for various oils and organic solvents, which are 3 times that reported previously. Owing to their hydrophobicity and oleophilicity, the as-obtained PDMS oil absorbents can selectively collect oils or organic solvents from water. The absorption process can be finished within tens of seconds. Furthermore, the absorbed oils or organic solvents can be recovered by compressing the oil absorben...
204 citations
••
TL;DR: In this paper, the authors derived expressions of interatomic force and heat current for many-body potentials such as the Tersoff, the Brenner, and the Stillinger-Weber potential used extensively in molecular dynamics simulations of covalently bonded materials.
Abstract: We derive expressions of interatomic force and heat current for many-body potentials such as the Tersoff, the Brenner, and the Stillinger-Weber potential used extensively in molecular dynamics simulations of covalently bonded materials. Although these potentials have a many-body nature, a pairwise force expression that follows Newton's third law can be found without referring to any partition of the potential. Based on this force formula, a stress applicable for periodic systems can be unambiguously defined. The force formula can then be used to derive the heat current formulas using a natural potential partitioning. Our heat current formulation is found to be equivalent to most of the seemingly different heat current formulas used in the literature, but to deviate from the stress-based formula derived from two-body potential. We validate our formulation numerically on various systems described by the Tersoff potential, namely three-dimensional silicon and diamond, two-dimensional graphene, and quasi-one-dimensional carbon nanotube. The effects of cell size and production time used in the simulation are examined.
204 citations
••
TL;DR: Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials, but additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.
Abstract: Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical effectiveness and tolerability in early clinical trials and has progressed into phase III trials. However, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition. This review summarizes preclinical and clinical development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292, and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.
204 citations
Authors
Showing all 50945 results
Name | H-index | Papers | Citations |
---|---|---|---|
Zhong Lin Wang | 245 | 2529 | 259003 |
Lei Jiang | 170 | 2244 | 135205 |
Yang Gao | 168 | 2047 | 146301 |
William A. Goddard | 151 | 1653 | 123322 |
Rui Zhang | 151 | 2625 | 107917 |
Xiaoyuan Chen | 149 | 994 | 89870 |
Fuqiang Wang | 145 | 1518 | 95014 |
Galen D. Stucky | 144 | 958 | 101796 |
Shu-Hong Yu | 144 | 799 | 70853 |
Wei Huang | 139 | 2417 | 93522 |
Bin Liu | 138 | 2181 | 87085 |
Jie Liu | 131 | 1531 | 68891 |
Han Zhang | 130 | 970 | 58863 |
Lei Zhang | 130 | 2312 | 86950 |
Jian Zhou | 128 | 3007 | 91402 |